4. 2). b Samtidig DMARD dækker en eller flere af følgende: methotrexat, chloroquin/ hydroxychloroquin, sulfasalazin, leflunomid, azathioprin, guld og anakinra. c HAQ; 0 = bedst, 3 = værst; 20 spørgsmål; 8 kategorier: påklædning og soignering, stå op, spise, gå, hygiene, nå, gribe og aktiviteter. d Reduktion i HAQ- DI på ≥ 0, 3 enheder fra baseline. e Efter 6 måneder fik patienterne mulighed for at indgå i et åbent forsøg.
p < 0.001, abatacept vs. placebo. a Fixed dose approximating 10 mg/ kg (see section 4.2). b Concurrent DMARDs included one or more of the following: methotrexate, chloroquine/ hydroxychloroquine, sulfasalazine, leflunomide, azathioprine, gold, and anakinra. c Health Assessment Questionnaire; 0 = best, 3 = worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. d Reduction in HAQ-DI of ≥ 0.3 units from baseline. e After 6 months, patients were given the opportunity to enter into an open-label study.